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ePTFE graft had no neocapillary formation even 6 months
after surgery. If synthetic vascular grafts are used for
CABG, the length of the graft may need to be long. Endothe-
lial cells can migrate into the graft from the (1) anastomotic
sites, (2) circulating blood, and (3) neocapillaries inside the
graft.21 It would take a long time to extend endothelial cells
from the anastomotic sites in a long graft for clinical applica-
tion. In addition to the extension from anastomotic sites and
the contribution from the circulating blood, migration from
the neocapillaries could carry endothelial cells to the center
of the graft. The neocapillary formation may be an advantage
to encourage endothelialization for synthetic vascular grafts.
Conclusions
A unique bioengineered microporous drug-eluting graft had
excellent patency throughout the 6months after implantation.
Biological agents, heparin and sirolimus, were impregnated
into the graft and encouraged luminal endothelialization
and neointimal formation. This graft has the potential to
become an implantable graft for CABG.
This study was a 6-month evaluation of a novel bioengi-
neered synthetic small-caliber graft involving 62 rabbits.
Because grafts were examined for histology and biomechan-
ical properties at several different time points, the number of
implanted grafts at each time point was small. However, data
of each time point were similar and consistent. The C grafts
were evaluated at only 6 months after surgery to be compared
with the H, HS, and ePTFE grafts. This is a preliminary study
in a rabbit aortic model. A longer term study will be needed to
evaluate the chronic efficacy of the eluted drugs. A large
animal coronary bypass graft model is needed to establish
clinical feasibility.
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CDDiscussion
Dr Robert Poston (Baltimore, Md). Why does sirolimus affect en-
dothelialization in stents but not in your grafts? What is the dif-
ference there? It is pretty well known that sirolimus reduces
re-endothelialization on top of an intracoronary stent, but it did
appear to have the same affect on the conduits in your research.
Dr Ishii.Regarding the endothelialization, in the SEMvariations
we can see it occurring beautifully inside the graft wall. When com-
pared with a non-sirolimus graft, sirolimus might therefore facilitate
good endothelialization. However, although both heparin and hepa-
rin-sirolimus grafts had a 100% patency rate during the 6 months
after surgery, the heparin-sirolimus grafts showed less neointima
formation than the heparin grafts.
Dr Poston.Maybe it is not just understood how that works. The
second question is related to your model. Themain concern that peo-
ple have regarding the use of small prosthetic grafts as bypass con-
duit for the heart would be acute thrombosis. Your control grafts in
your model didn’t acutely thrombose, even the PTFE graft without
heparin. So do you think that this model is adequately testing the key
limitation of these grafts?ic and Cardiovascular Surgery c Volume 135, Number 6 1245
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CDDr Ishii. Actually you are right. This is a good question,
Dr Poston. We didn’t see any acute thrombosis in either the con-
trol grafts without drugs or in the heparin and sirolimus grafts.
However, half of the ePTFE grafts in this study occluded during
the 6 months after surgery. When compared with our micropo-
rous polyurethane grafts, the ePTFE grafts showed less endothe-
lialization. As I showed you with the SEM data, out of all the
grafts the heparin-sirolimus grafts had the most beautiful layer
of endothelial cells.
Dr Beat H. Walpoth (Geneva, Switzerland). I think what are
you doing is a bit controversial. Our series on rapamycin-treated
grafts was published in the European Journal of Cardiothoracic
Surgery in 2000, and we showed that there is a significant reduc-
tion of intimal hyperplasia. I think your data were not significant.
In addition, we had no endothelialization; we had much more
thrombus formation. So this goes along with what is now seen
in the drugeluting stents. In medicine, everything is a question
of dosage. I am not sure if eventually your dosage was not potent1246 The Journal of Thoracic and Cardiovascular Surgery c Juenough to achieve this goal. Anyhow, they are some interesting
results.
Dr Valavanur Subramanian (New York, NY). Just a brief com-
ment to bring you up to date. There are drug-eluting wraps around
the grafts that have already been in clinical use in arteriovenous fis-
tula. Our colleagues in endovascular cardiology have now taken
a different form of wrap around the distal anastomosis with
a PTFE or saphenous vein graft. The first feasibility trial will soon
be done in coronary bypass grafts pretty, and the 6-month patency
in the arteriovenous fistula has been excellent. So there is already
a clinical movement on this approach.
Dr Cliff Choong (Cambridge, United Kingdom). Do you have
any data on longer-term results, and are you planning to do any
long-term experimental studies?
Dr Ishii. Actually this is just a preliminary rabbit model. We
don’t have any longer-term data yet. As you mentioned, we should
do a larger animal study and longer-term study before attempting
any clinical applications. We are planning that now.ne 2008
